Procyon Advisors LLC acquired 2,905 shares of IDEXX Laboratories in Q4, valued at about $1.97 million. Several other institutional investors also adjusted their stakes, with notable increases by Bank of New York Mellon and JPMorgan Chase. Insider sales occurred recently, with two executive vice presidents reducing their holdings significantly. Analysts have mixed views, with price targets lowered but mostly positive ratings, resulting in a consensus "Moderate Buy." IDEXX reported slightly missed EPS but revenue growth, and projects strong earnings for FY 2026. The stock trades near $577 with a market cap of $45.9 billion.
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
